Unraveling the Role of PCDH9 in Breast Cancer and Identifying Therapeutic Strategies for PCDH9-Deficient Tumors
In summary, our study identified PCDH9 as a tumor suppressor in breast cancer and highlighted TAS-102 as a potential therapeutic option for tumors with low PCDH9 expression or deficiency. The specific interaction between TAS-102 and PCDH9 warrants further exploration, providing deeper insights into its mode of action in treating PCDH9-deficient breast cancer.
Authors
- Lulu Liu (ORCID: https://orcid.org/0000-0002-2563-3379)
- Yong Liu (ORCID: https://orcid.org/0000-0001-8315-9751)
- Ruixi Li (ORCID: https://orcid.org/0000-0002-0950-7532)
- Jinsong Li (ORCID: https://orcid.org/0000-0003-3456-662X)
- Tang Jiang
Institutions
- Central South University (CN)
- Yueyang Second People's Hospital (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/bctt.s476083
- Citations
- 3
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- Central South University
- Xiangya Hospital, Central South University